A blood-based platform using the aforementioned FoundationOne CDx assay was capable of measuring TMB in plasma samples (blood TMB, or bTMB) in two large randomized clinical trials (POPLAR and OAK); bTMB correlated with TMB measured in tumor biopsy samples in NSCLC, and therefore has the potential to identify patients who derive clinical benefit from anti-PD-L1 treatment (such as atezolizumab). The gene discussed is CD274; the disease is neoplasm.